ABBOTT LABORATORIES — Director's Dealing 2022

Feb 24, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2022-02-18

Reporting Person: Boudreau Philip P (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-02-18	Common shares without par value	A	5351	—	Acquired	22227	Direct
2022-02-22	Common shares without par value	F	966	$116.79	Disposed	21261	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-18	Option (right to buy)	$117.58	A	24938	Acquired	2032-02-17	Common Shares (24938)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	340	Indirect

Footnotes

F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

F2: Balance in the Abbott Laboratories Stock Retirement Trust as of February 18, 2022.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,312 on February 18, 2023, 8,313 on February 18, 2024, and 8,313 on February 18, 2025.